• Clinical science



Content currently under development

A pheochromocytoma is a catecholamine-secreting tumor typically located in the adrenal medulla. Pheochromocytomas are usually benign (∼ 90% of cases) but may also be malignant. Classic clinical features are due to excess sympathetic nervous system stimulation and involve episodic blood pressure crises with paroxysmal headaches, diaphoresis, heart palpitations, and pallor. However, a pheochromocytoma may also present asymptomatically or with persistent hypertension. Elevated catecholamine metabolites in the plasma or urine confirm the diagnosis, while imaging studies in patients with positive biochemistry are used to determine the location of the tumor. Surgical resection is the treatment of choice, but is only carried out once alpha blockade with phenoxybenzamine has become effective.


Content currently under development

  • Age range: 3rd–5th decades of life
  • Present in up to 1% of all hypertensive patients


Epidemiological data refers to the US, unless otherwise specified.


Content currently under development

“10 percent rule”- roughly 10% of pheochromocytomas are: extra-adrenal, multiple, bilateral, malignant, pediatric cases, not associated with hypertension, show calcifications on imaging!


Clinical features

Content currently under development

Clinical presentation is related to fluctuating levels of excess epinephrine, norepinephrine, and dopamine.

Hypertensive crises can be triggered by palpation of the tumor on abdominal exam!



Content currently under development

Laboratory tests

Other diagnostic tests

  • 24-hour ambulatory blood pressure monitoring
  • Adrenal/abdominal CT or MRI (after positive biochemistry tests to localize tumor)
    • Scintigraphy (MIBG)
  • Other imaging to search for potential additional tumors in patients with pheochromocytoma and MEN2A, MEN2B, NF1, or VHL



Content currently under development

  • Operable disease: Management consists of preoperative blood pressure management and then surgery.
    • Preoperative blood pressure management: Combined alpha and beta-adrenergic blockade
    • Treatment of choice: laparoscopic tumor resection (adrenalectomy)
      • "No-touch" technique
      • Open surgical resection is reserved for large or invasive tumors.
    • Prognosis and follow-up
      • Over half of all patients with benign pheochromocytoma become normotensive after tumor resection.
      • Long-term annual biochemical monitoring for recurrence is indicated in all patients.
      • Benign pheochromocytoma recurs in ∼ 15% of patients, usually 5–15 years after surgery
      • The prognosis for malignant pheochromocytoma is highly variable

Starting beta blockers before alpha blockade is contraindicated. Beta blockers cancel out the vasodilatory effect of peripheral beta-2 adrenoceptors, potentially leading to unopposed alpha-adrenoceptor stimulationvasoconstrictionhypertensive crisis.


  • 1. National Cancer Institute. Pheochromocytoma and Paraganglioma Treatment (PDQ®)–Health Professional Version. https://www.cancer.gov/types/pheochromocytoma/hp/pheochromocytoma-treatment-pdq#link/_64_toc. Updated July 10, 2015. Accessed February 13, 2017.
  • 2. Kasper DL, Fauci AS, Hauser SL, Longo DL, Lameson JL, Loscalzo J. Harrison's Principles of Internal Medicine. New York, NY: McGraw-Hill Education; 2015.
  • 3. Agabegi SS, Agabegi ED. Step-Up To Medicine. Baltimore, MD, USA: Wolters Kluwer Health; 2015.
  • 4. Blake MA. Pheochromocytoma. In: Griffing GT. Pheochromocytoma. New York, NY: WebMD. https://emedicine.medscape.com/article/124059. Updated October 10, 2017. Accessed January 30, 2018.
  • 5. Le T, Bhushan V, Chen V, King M. First Aid for the USMLE Step 2 CK. McGraw-Hill Education; 2015.
  • 6. Zuber SM, Kantorovich V, Pacak K. Hypertension in Pheochromocytoma: Characteristics and Treatment. Endocrinol Metab Clin North Am. 2011; 40(2): pp. 295–311. doi: 10.1016/j.ecl.2011.02.002.
last updated 04/19/2018
{{uncollapseSections(['mq0V_S', 'nq07_S', 'Lq0w_S', '6q0jzS', 'qq0CzS', '7q04-S'])}}